<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478462</url>
  </required_header>
  <id_info>
    <org_study_id>DCL-17-001</org_study_id>
    <nct_id>NCT03478462</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma</brief_title>
  <acronym>CLOVER-2</acronym>
  <official_title>An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellectar Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cellectar Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or&#xD;
      refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain&#xD;
      tumors for which there are no standard treatment options with curative potential.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Even with standard, highly toxic multimodality therapies and salvage regimen, most pediatric&#xD;
      patients with primary metastatic or relapsed solid tumors are confronted with a poor&#xD;
      prognosis. For these patients there is currently no accepted successful treatment regimen.&#xD;
      There is a need for new drugs, including targeted radiopharmaceuticals, preferably with&#xD;
      cancer-specific uptake and broad applicability for these rare pediatric malignancies.&#xD;
&#xD;
      CLR 131 is a radioiodinated therapeutic that exploits the selective uptake and retention of&#xD;
      phospholipid ethers (PLEs) by malignant cells. Cellectar Biosciences' novel cancer-targeted&#xD;
      small-molecule compound (CLR1404) is radiolabeled with the isotope iodine-131 (I-131). CLR&#xD;
      131 has demonstrated tumor selective uptake across numerous adult and pediatric cancer cell&#xD;
      types. Therapeutic efficacy has been demonstrated in various pediatric and adult-type cancer&#xD;
      xenograft models, confirming the ability of CLR 131 to target tumors.&#xD;
&#xD;
      Based on the critical unmet medical need for effective agents with novel mechanisms of action&#xD;
      in relapsed pediatric cancers and initial preclinical and clinical experience with&#xD;
      radioiodinated CLR1404, Cellectar Biosciences has chosen to assess CLR 131 in a phase 1&#xD;
      pediatric trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLT)</measure>
    <time_frame>up to 64 days</time_frame>
    <description>DLT will be assessed by physical examination, vital signs, and laboratory values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of recommended phase 2 dose of CLR 131 in children, adolescents, and young adults</measure>
    <time_frame>until non-tolerated dose is defined; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)</time_frame>
    <description>Dose and regimen to be used in Phase 2 trials of CLR 131 in children, adolescents, and young adults</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of preliminary antitumor activity of CLR 131 in children, adolescents, and young adults</measure>
    <time_frame>through Day 85</time_frame>
    <description>Response assessment per applicable criteria (e.g., Neuroblastoma Response Criteria (modified); RECIST 1.1; positron emission tomography response criteria in solid tumors (PERCIST); RANO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of therapeutic activity of CLR 131 in children, adolescents, and young adults</measure>
    <time_frame>up to 22 days post initial infusion</time_frame>
    <description>Assessment via 131-I/CLR 131 SPECT/CT scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of event free survival following CLR 131 infusion in children, adolescents, and young adults</measure>
    <time_frame>1 month to 5 years</time_frame>
    <description>Time from first infusion of CLR 131 until progression or recurrence of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of overall survival following CLR 131 infusion in children, adolescents, and young adults</measure>
    <time_frame>1 month to 5 years</time_frame>
    <description>Time from first infusion of CLR 131 until death due to any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine dosimetry of CLR 131 in children, adolescents, and young adults</measure>
    <time_frame>up to 15 days post initial infusion</time_frame>
    <description>Assessment of dosimetry via whole body planar imaging</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pediatric Solid Tumor</condition>
  <condition>Pediatric Lymphoma</condition>
  <condition>Pediatric Brain Tumor</condition>
  <condition>DIPG</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ewing Sarcoma</condition>
  <condition>Rhabdomyosarcoma</condition>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>CLR 131</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLR 131 intravenous administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLR 131</intervention_name>
    <description>IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose</description>
    <arm_group_label>CLR 131</arm_group_label>
    <other_name>I-131-CLR1404</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Patients&#xD;
&#xD;
          -  Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g.,&#xD;
             neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain&#xD;
             tumors that are clinically or radiographically suspected to be relapsed, refractory,&#xD;
             or recurrent for which there are no standard treatment options with curative&#xD;
             potential. Note: patients with diffuse intrinsic pontine glioma (DIPG) may enroll&#xD;
             without histological or cytological confirmation.&#xD;
&#xD;
          -  ≥ 2 years of age and ≤ 25 years of age at time of consent/assent&#xD;
&#xD;
          -  If ≥ age 16 years, Karnofsky performance status of ≥ 60. If &lt; age 16 years, Lansky&#xD;
             performance status ≥ 60&#xD;
&#xD;
          -  Platelets ≥ 75,000/µL (last transfusion, if any, must be at least 1 week prior to&#xD;
             study registration, and, unless deemed medically necessary, no transfusions are&#xD;
             allowed between registration and dosing)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 750/µL&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL (last transfusion must be at least 1 week prior to study&#xD;
             registration, and, unless deemed medically necessary, no transfusions are allowed&#xD;
             between registration and dosing)&#xD;
&#xD;
          -  Using the bedside Schwartz formula, estimated GFR (creatinine clearance) &gt; 60&#xD;
             ml/min/1.73m2&#xD;
&#xD;
          -  Alanine aminotransferase &lt; 3 × ULN&#xD;
&#xD;
          -  Bilirubin &lt; 2 × ULN&#xD;
&#xD;
          -  Patients who have undergone autologous or allogeneic bone marrow transplant must be at&#xD;
             least 3 months from transplant.&#xD;
&#xD;
          -  Patients enrolling at total dose levels &gt; 30 millicurie (mCi)/m2 must have&#xD;
             availability or ability to collect an autologous hematopoietic stem cell back-up&#xD;
             product prior to CLR 131 administration. At minimum, 2 x 10^6/kg cryopreserved CD34+&#xD;
             cells must be available.&#xD;
&#xD;
          -  Patient or his or her legal representative is judged by the Investigator to have the&#xD;
             initiative and means to be compliant with the protocol.&#xD;
&#xD;
        Patients with Pediatric Solid Tumor or Lymphoma&#xD;
&#xD;
          -  At least 1 measurable lesion with longest diameter of at least 10 mm. Patients with a&#xD;
             lesion(s) that are determined to be Metaiodobenzylguanidine (MIBG) or positron&#xD;
             emission tomography (PET) positive may be enrolled at the investigator's discretion,&#xD;
             even if not associated with a measurable lesion of at least 10 mm. Patients with&#xD;
             neuroblastoma who have detectable disease may enroll provided they meet the&#xD;
             requirements of the International Neuroblastoma Response Criteria.&#xD;
&#xD;
          -  Patients with known brain metastases must have completed any radiotherapy or systemic&#xD;
             treatments for brain metastases prior to enrollment; by investigator assessment be&#xD;
             considered stable with no new signs or symptoms for at least 1 month, and on a stable&#xD;
             dose of steroids (unchanged for three weeks prior to registration or on a steroid&#xD;
             tapering regimen).&#xD;
&#xD;
        Patients with Recurrent or Refractory Brain Tumors&#xD;
&#xD;
          -  At least 1 measurable lesion with longest diameter of at least 10 mm on any imaging&#xD;
             sequence.&#xD;
&#xD;
          -  Patients with previously known neurological deficits must be clinically stable at time&#xD;
             of enrollment and able to complete all study related procedures. Patients with&#xD;
             documented or newly diagnosed neurological deficits will be enrolled at the&#xD;
             investigator's discretion.&#xD;
&#xD;
          -  If patient receives steroids for neurological symptom control, the dose must be stable&#xD;
             (unchanged for three weeks prior to registration) or on a steroid tapering regimen.&#xD;
             Initiation of steroids per routine care immediately prior to CLR 131 dosing is&#xD;
             acceptable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving active treatment for central nervous system metastases or those&#xD;
             that are likely to require active treatment during anticipated participation in this&#xD;
             trial. Patients with stable brain metastases treated with steroids may enroll at the&#xD;
             investigator's discretion&#xD;
&#xD;
          -  For solid tumor and lymphoma patients only, central nervous system involvement unless&#xD;
             previously treated with surgery, systemic therapy, or radiotherapy with the patient&#xD;
             neurologically stable. Patients with metastatic brain tumors that have been previously&#xD;
             treated are allowed, provided the patient is neurologically stable (determined at the&#xD;
             investigator's discretion).&#xD;
&#xD;
          -  Antitumor therapy or investigational therapy, within 2 weeks of dosing. For certain&#xD;
             types of radiation (craniospinal, total abdominal, whole lung [spot irradiation to&#xD;
             skull-based metastases is not considered craniospinal radiation for the purposes of&#xD;
             this study]), at least 3 months must have elapsed. No washout is required for&#xD;
             palliative focal radiation. NOTE: Patients participating in non-interventional&#xD;
             clinical trials (i.e., non-drug) are allowed to participate in this trial&#xD;
&#xD;
          -  Patients previously treated with iodine-131 (131I)-MIBG who have already received a&#xD;
             cumulative I-131 dose &gt; 54 mCi/kg or who would exceed 54 mCi/kg by participating in&#xD;
             this trial, are not eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Friend, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cellectar Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kate Oliver</last_name>
    <phone>608-327-8125</phone>
    <email>clinical@cellectar.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Sweeters</last_name>
      <phone>650-721-4074</phone>
      <email>nancy.sweeters@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Allison Pribnow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Glade-Bender, MD</last_name>
      <email>gladebej@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Julia Glade-Bender, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Backus</last_name>
      <email>lori.backus@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Josephy Pressey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy McCarthy</last_name>
      <phone>832-824-4804</phone>
      <email>ksmccart@txch.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Foster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Weiland</last_name>
      <phone>608-890-8070</phone>
      <email>PedsHemOncResearch@lists.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Diane Puccetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Samolej</last_name>
      <email>Anna.Samolej@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Dinisha Govender, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Morgenstern, MD</last_name>
      <email>nait.info@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel Morgenstern, MBChir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>medulloblastoma</keyword>
  <keyword>ependymoma</keyword>
  <keyword>high-grade glioma</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>DIPG</keyword>
  <keyword>diffuse-intrinsic pontine glioma</keyword>
  <keyword>ATRT</keyword>
  <keyword>atypical teratoid rhabdoid tumor</keyword>
  <keyword>PNET</keyword>
  <keyword>primitive neuroectodermal tumor</keyword>
  <keyword>gliosarcoma</keyword>
  <keyword>gliomatosis cerebri</keyword>
  <keyword>neuroblastoma</keyword>
  <keyword>rhabdomyosarcoma</keyword>
  <keyword>Ewing sarcoma</keyword>
  <keyword>osteosarcoma</keyword>
  <keyword>DSRCT</keyword>
  <keyword>desmoplastic small round cell tumor</keyword>
  <keyword>sarcoma</keyword>
  <keyword>malignant germ cell tumor</keyword>
  <keyword>synovial sarcoma</keyword>
  <keyword>rare cancer</keyword>
  <keyword>Wilms tumor</keyword>
  <keyword>lymphoma</keyword>
  <keyword>Hodgkin Lymphoma</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

